Login to Your Account

Taiwan Liposome knee pain drug meets phase I/II target

By Shannon Ellis
Staff Writer

Tuesday, January 10, 2017

SHANGHAI – Taiwan Liposome Co. is hoping to give patients with osteoarthritis of the knee a better option for pain management with TLC599, a steroid API wrapped in a sustained release liposome delivery package.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription